Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 29:13:1005189.
doi: 10.3389/fendo.2022.1005189. eCollection 2022.

Osteocytes and the pathogenesis of hypophosphatemic rickets

Affiliations
Review

Osteocytes and the pathogenesis of hypophosphatemic rickets

Miwa Yamazaki et al. Front Endocrinol (Lausanne). .

Abstract

Since phosphorus is a component of hydroxyapatite, its prolonged deprivation affects bone mineralization. Fibroblast growth factor 23 (FGF23) is essential for maintaining phosphate homeostasis and is mainly produced by osteocytes. FGF23 increases the excretion of inorganic phosphate (Pi) and decreases the production of 1,25-dihydroxyvitamin D in the kidneys. Osteocytes are cells of osteoblastic lineage that have undergone terminal differentiation and become embedded in mineralized bone matrix. Osteocytes express FGF23 and other multiple genes responsible for hereditary hypophosphatemic rickets, which include phosphate-regulating gene homologous to endopeptidase on X chromosome (PHEX), dentin matrix protein 1 (DMP1), and family with sequence similarity 20, member C (FAM20C). Since inactivating mutations in PHEX, DMP1, and FAM20C boost the production of FGF23, these molecules might be considered as local negative regulators of FGF23. Mouse studies have suggested that enhanced FGF receptor (FGFR) signaling is involved in the overproduction of FGF23 in PHEX-deficient X-linked hypophosphatemic rickets (XLH) and DMP1-deficient autosomal recessive hypophosphatemic rickets type 1. Since FGFR is involved in the transduction of signals evoked by extracellular Pi, Pi sensing in osteocytes may be abnormal in these diseases. Serum levels of sclerostin, an inhibitor Wnt/β-catenin signaling secreted by osteocytes, are increased in XLH patients, and mouse studies have suggested the potential of inhibiting sclerostin as a new therapeutic option for the disease. The elucidation of complex abnormalities in the osteocytes of FGF23-related hypophosphatemic diseases will provide a more detailed understanding of their pathogenesis and more effective treatments.

Keywords: fibroblast growth factor 23; mutation; osteocyte; phosphate; rickets.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Complex abnormalities in osteocytes of Phex-deficient Hyp mice. In Hyp osteocytes, the expression of Fgfr1 is increased and enhanced FGFR signaling may underlie the overproduction of FGF23. The overproduction of FGF23 leads to the renal wasting of inorganic phosphate (Pi) and impaired vitamin D metabolism. Hyp osteocytes produce an increased amount of sclerostin, which may stimulate the production of FGF23. The production of osteopontin is up-regulated in Hyp osteocytes, which impairs skeletal mineralization. The expression of Dmp1 and Fam20c is also increased.

Similar articles

Cited by

References

    1. Michigami T, Kawai M, Yamazaki M, Ozono K. Phosphate as a signaling molecule and its sensing mechanism. Physiol Rev (2018) 98(4):2317–48. doi: 10.1152/physrev.00022.2017 - DOI - PubMed
    1. Michigami T, Ozono K. Roles of phosphate in skeleton. Front Endocrinol (Lausanne). (2019) 10:180. doi: 10.3389/fendo.2019.00180 - DOI - PMC - PubMed
    1. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. . Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin d metabolism. J Clin Invest. (2004) 113(4):561–8. doi: 10.1172/JCI200419081 - DOI - PMC - PubMed
    1. Fukumoto S. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment. J Mol Endocrinol (2021) 66(2):R57–65. doi: 10.1530/JME-20-0089 - DOI - PubMed
    1. Delgado-Calle J, Bellido T. The osteocyte as a signaling cell. Physiol Rev (2022) 102(1):379–410. doi: 10.1152/physrev.00043.2020 - DOI - PMC - PubMed

Publication types

MeSH terms